Evaluating muscle oxygenation in COPD patients during respiratory fatigue
Examining the Relationship Between Respiratory Muscle Fatigue and Lower Extremity Muscle Oxygenation in Chronic Obstructive Pulmonary Disease Patients.
NA · Istanbul Medipol University Hospital · NCT06217276
This study is testing how muscle oxygen levels change in people with COPD during breathing fatigue to see how it compares to healthy individuals.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Istanbul Medipol University Hospital (other) |
| Locations | 1 site (Istanbul, Zeytinburnu) |
| Trial ID | NCT06217276 on ClinicalTrials.gov |
What this trial studies
This study investigates changes in oxygenation levels of the vastus lateralis muscle in patients with Stage 2-3 COPD using the Moxy device, which measures functional infrared oxygen levels. Participants will undergo a respiratory muscle fatigue protocol to assess how their muscle oxygenation responds compared to healthy controls. The study aims to provide insights into the relationship between respiratory muscle fatigue and lower extremity muscle oxygenation in COPD patients.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with Stage 2-3 COPD who have been stable on their medications for at least four weeks.
Not a fit: Patients with severe comorbidities, recent acute COPD exacerbations, or other significant respiratory diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of muscle oxygenation in COPD, potentially leading to improved management strategies for patients.
How similar studies have performed: While the specific approach of this study may be novel, similar studies have explored muscle oxygenation in respiratory conditions, indicating potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Having a diagnosis of Stage 2-3 COPD according to the following clinical diagnostic criteria according to the American Thoracic and European Respiratory Societies (ATS-ERS). * Having been using the same medications for the last 4 weeks Exclusion Criteria: * Patients with severe comorbid diseases, unstable coronary artery disease, collagen vascular diseases and requiring high-flow oxygen therapy (˃ 3-4 L\\min). * Presence of any vascular problem that may affect lower extremity muscle oxygenation * Presence of another respiratory system disease other than COPD * Patients who have had an acute COPD exacerbation in the last 4 weeks * Patients experiencing COPD exacerbations during the study protocol * Presence of fatty tissue or scar tissue at the measurement points, which may impair the measurement quality. * Have already participated in another clinical trial within the last 30 days that may affect the results of the study. Inclusion Criteria for Healthy Cases * Being over 18 years of age * Not having any diagnosed chronic disease * Not being a smoker
Where this trial is running
Istanbul, Zeytinburnu
- Yedikule Chest Disease Hospital — Istanbul, Zeytinburnu, Turkey (Türkiye) (RECRUITING)
Study contacts
- Study coordinator: ESRA PEHLİVAN
- Email: fztesrakambur@yahoo.com
- Phone: 09050585279
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COPD